Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA (ZX008) in Dravet Syndrome
pharmaceutical investing Zogenix Announces Positive Top-line Results from Second Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Standard Uranium Retains 100% Unencumbered Ownership of the Sun Dog Project Through Conclusion of Property Option Agreement
RZOLV Technologies Appoints Mary Ellen Thorburn to the Board of Directors; Announces the Retirement of Darryl Yea
